Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction
NCT ID: NCT00748982
Last Updated: 2011-06-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
16 participants
INTERVENTIONAL
2008-08-31
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
NCT04986202
Explorative Study of AZD1305 in Atrial Fibrillation Patients
NCT00643448
Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.
NCT03756285
A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients
NCT01396226
A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy
NCT07241104
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
AZD1305
iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
2
Placebo
iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD1305
iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
Placebo
iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mildly/moderately decreased heart function
* Regular heart rhythm
Exclusion Criteria
* Child bearing potential
* Severely decreased heart function
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helen Lund, MD
Role: STUDY_DIRECTOR
AstraZeneca R&D, Mölndal, Sweden
Marianne Hartford, MD
Role: PRINCIPAL_INVESTIGATOR
AstraZeneca, Clinical Pharmacology Unit at Sahlgrenska University Hospital, Sweden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Gothenburg, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-001254-41
Identifier Type: -
Identifier Source: secondary_id
D3190C00013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.